Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response
© 2023 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers..
Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (n = 8) demonstrated a high level of correlation with the PDX (n = 2) and clinical response in patients (n = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Bioengineering & translational medicine - 9(2024), 2 vom: 27. März, Seite e10624 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiong, Qiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bladder cancer |
|---|
| Anmerkungen: |
Date Revised 05.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/btm2.10624 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36925693X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36925693X | ||
| 003 | DE-627 | ||
| 005 | 20240305232809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/btm2.10624 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM36925693X | ||
| 035 | |a (NLM)38435820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiong, Qiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. | ||
| 520 | |a Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (n = 8) demonstrated a high level of correlation with the PDX (n = 2) and clinical response in patients (n = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bladder cancer | |
| 650 | 4 | |a chemotherapy sensitivity | |
| 650 | 4 | |a microfluidic chip | |
| 650 | 4 | |a personalized treatment | |
| 650 | 4 | |a tumor spheroid | |
| 700 | 1 | |a Liu, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Yidie |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ziwei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Hongliang |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Tianhai |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Weihua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhensheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Shuxiong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Chuanliang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioengineering & translational medicine |d 2016 |g 9(2024), 2 vom: 27. März, Seite e10624 |w (DE-627)NLM267182767 |x 2380-6761 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:2 |g day:27 |g month:03 |g pages:e10624 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/btm2.10624 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 2 |b 27 |c 03 |h e10624 | ||